Stem Cell Banking Market Analysis by Service Type (Collection & Transportation, Processing, Analysis, and Storage); by Utilization (Used, and Unused); by Cell Type (Umbilical Cord Stem Cell, Cord Blood, Cord Tissue, Placenta, Adult Stem Cell, and Embryonic Stem Cell), and Bank Type (Public, and Private) – Global Supply & Demand Analysis & Opportunity Outlook 2023-2035

Buy Now Report ID: 4776 | Published Date: Apr 01, 2023

Global Stem Cell Banking Market Size, Forecast, and Trend Highlights Over 2023 – 2035

The global stem cell banking market size is estimated to reach ~USD 34.28 Billion by the end of 2035 by growing at a CAGR of ~11.20% over the forecast period, i.e., 2023 – 2035. In addition to this, in the year 2022, the market size of stem cell banking was ~USD 9.59 Billion. The growth of the market can be attributed to growing investment in stem cell research by number of nations owing to stem cell capacity to completely transform the way diseases are treated in people. The Novo Nordisk Foundation was anticipated to contribute up to USD 340 million over ten years to the creation of a worldwide stem cell research facility in 2022. Moreover, stem cell is a complex and continuous to conduct research on. Therefore, this factor is also anticipated to boost the investment on stem cell research.

Moreover, there has been growing need for stem cell transplant all across the world. Around 12 lakh transplants have been performed utilizing stem cells globally during the past 50 years. Presently, there are more than 49,000 transplants performed annually, and the number is rising. However, stem cells still need to be kept in reserve for potential autologous or allogeneic applications, even when they are employed for medical treatments. Through using this method, less human tissues would be used, and more studies could be compared. Hence, stem cell banks have been set up for both current research and therapy, raising some ethical, legal, and social concerns in the process. Hence, owing to this market is estimated to grow.

Get more information on this report: Request Free Sample PDF

Global Stem Cell Banking Market: Key Insights

Base Year


Forecast Year




Base Year Market Size (2022)

~ USD 9.59 Billion

Forecast Year Market Size (2035)

~ USD 34.28 Billion

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)



Global Stem Cell Banking Market: Growth Drivers and Challenges


Growth Drivers

  • Growing Prevalence for Cardiovascular Disease

About 29 million adults in the United States had heart disease as of 2018. Heart disease is the biggest cause of death in the US, killing over 646,000 Americans each year. Cardiovascular disease is generally brought on by issues with the blood arteries. Stem cells that matched normal blood vessels in both look and function are used to create new blood vessels. Since, they could be utilized to repair or regenerate a number of human tissues, stem cells from the bank could aid people in managing disorders including vascular and cardiovascular disease.

  • Rise in Number of People with Diabetes Type I

T1D affects about 2 million people in the United States. Also, in the US, approximately 64,000 people receive a diagnosis each year. Moreover, by 2040, about 3 million Americans are anticipated to have T1D. Insulin deficiency or insufficient production in the body is a symptom of diabetes type I, which is caused by malfunctioning pancreatic cells. Preserved stem cells may be employed to transplant pancreatic stem cells into people with type 1 diabetes. These cells may be able to replace insulin-producing cells that have been damaged by an immune system in patients, solving the issue.

  • Surge in Approval of Product by Regulatory Authorities

An investigational new drug (IND) application for BCDA-04, a proprietary allogeneic mesenchyme cell (MSC) population that is Neurokinin-1 receptor-positive (NK1R+), was approved by the U.S. Food and Drug Administration (FDA) in 2022, according to BioCardia, Inc., a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases.

  • Growth in Prevalence of Blood Related Issues

There were about 23,709 leukemia-related deaths and about 59,609 new cases of all types of leukemia in United States in 2023. Hence owing to this the demand for stem cell banking is estimated to grow. Hematopoietic progenitor and stem cells are abundant in the placenta and cord blood (HPCs). They are successful in treating disorders such as leukemia, sickle cell anaemia, and other immunodeficiencies as a result of their capacity to develop into all other types of blood cells.

  • Upsurge in Need for Brain Disease Treatment

In America, neurological disorders caused about 533,171 fatalities in 2019, of which approximately 320,042 were women and about 213,128 were men. Hence, the need for treatment is growing. The loss of cells following damage is linked to many different brain diseases. Stem cells could be used in the treatment of these conditions.


  • High Operation Cost - The costs associated with processing samples, determining their quality, preserving and storing them add up for cell, tissue, and biobanks. This excludes expenditures for the purchase and upkeep of expensive tools, chemicals, and consumables. As a result, service providers incur substantial operational costs. Additionally, it is anticipated that the expensive licensing/approval process for the establishment of stem cell banks in developed countries as well as the increasingly strict and mandatory regulatory requirements related to stem cell preservation and banking would then further increase the overall operational costs for stem cell banking service providers.
  • Absence of Proper Handling Such as Freezing, Storage, and Warming
  • Inaccessibility of Stem Cell Bank to People  

Global Stem Cell Banking Market Segmentation

The global stem cell banking market is segmented and analyzed for demand and supply by cell type into umbilical cord stem cell, cord blood, cord tissue, placenta, adult stem cell, and embryonic stem cell. Out of which, the cord blood segment is anticipated to garner the highest revenue by the end of 2035. The growth of the segment can be attributed to the growing registration of cord blood donor. There were more than 265,000 cord blood units registered as donors in United States. More than 114,000 units from the National Cord Blood Inventory (NCBI) was included in this figure, and more than 3,000 NCBI units was estimated to be added in 2021. Moreover, umbilical cord blood is also used to extract stem cells for transplantation. The blood that remains in an umbilical cord after a baby is born is known as umbilical cord blood. Until, it is utilized in a cord blood transplant, the cord blood is frozen and kept in storage. Compared to other bone marrow transplant choices, cord blood has fewer stem cell options. Yet, compared to bone marrow stem cells, those found in cord blood have a greater capacity to proliferate blood cells. Since, cord blood cells have not been exposed to pathogens, they are also immunologically immature. This increases their tolerance for tissue mismatches between the patient's and the lead cells. Patients who are in need of transplants however lack a fully matched donor could use them. Hence, owing to this the segment is estimated to grow.

The global stem cell banking market is also segmented and analyzed for demand and supply by bank type into public and private. Amongst which, the private segment is anticipated to have the significant growth over the forecast period. An individual or family may store their stem cells in private banking for later use. Moreover, in the event that a family member is later identified as having an illness that could be treated with stem cells, this kind of bank provides a form of health insurance to each family. Hence, this bank is known for providing premium services which would drive the growth of the segment. Additionally, the American Academy of Pediatrics (AAP) recommends to only take private lead banking into account if a family member suffers from a hereditary illness that could be helped by stem cell therapies. The reason for this is that a non-family donation may not be a good match for the sick member of the family, whereas cord blood from the kid might.

Our in-depth analysis of the global stem cell banking market includes the following segments:


       By Service Type

  • Collection & Transportation
  • Processing
  • Analysis
  • Storage

       By Utilization

  • Used
  • Unused

      By Cell Type

  • Umbilical Cord Stem Cell
  • Cord Blood
  • Cord Tissue
  • Placenta
  • Adult Stem Cell
  • Embryonic Stem Cell

     By Bank Type

  • Public
  • Private

Global Stem Cell Banking Market Regional Synopsis


The market share of stem cell banking in North America, amongst the market in all the other regions, is projected to have the highest growth, backed by growing prevalence of chronic disease, along with well-established medical infrastructure. Six in ten Americans have at least one chronic illness, such as diabetes, cancer, heart disease, and stroke. The top causes of death and disability in America are these and other chronic disorders. Moreover, genetic problems, other reproduction-related disorders, and infertility are on rise in this region. These together have a significant negative influence on the mental wellbeing of those who experience it, which lowers their quality of life. Hence, the need for stem cell banking in this region is estimated to boost. Additionally, with more research and development operations in the healthcare sector, this could also be ascribed to the sector's expanding developments. The market is also expanding as a result of the increased initiatives being taken by different research institutes and organizations to improve medical facilities and services.

The Asia Pacific stem cell banking market is estimated to be the second largest, to have the highest growth. The growth of the market in this region can be attributed to growing adoption of medical advancement such as stem cell treatment. For instance, India is one of the top international destinations for medical tourism. India is a pioneer in embracing medical breakthroughs. The top stem cell experts work for them. When compared to other nations, the price of stem cell therapy is also much lower in India. Therefore, the growth in India could boost the overall growth of Asia Pacific region. Moreover, the increased incidence of chronic illnesses such as cancer, diabetes, and cardiovascular disorders as well as the region's ageing population are to blame for the region's increasing demand for stem cell therapy, further boosting market growth. Future market expansion in this region is also anticipated to be aided by increased stem cell research initiatives, collaborations between academics and industry, and public understanding of the therapeutic advantages of stem cell therapy.

Additionally, the market in Europe region is also expected to have significant growth over the forecast period, backed by presence of top key players in this region. Also, there has been growing development of advanced storage devices in order to store stem cell in the banking services. Moreover, Ireland, Sweden, Finland, Belgium, Greece, Britain, Denmark, and the Netherlands are among the European Union nations that allow stem cell research involving human embryos, when it is banned from most of the top growing countries in this field.



Get more information on this report: Request Free Sample PDF

Top Featured Companies Dominating the Global Stem Cell Banking Market

    • CBR Systems Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Global Cord Blood Corporation
    • Cordlife Group Limited
    • Cordvidadvdfvdsfsdf
    • Cryo-Cell International, Inc.
    • BrainStorm Cell Limited
    • Cryoviva Biotech Pvt. Ltd.
    • Lifecell International Private Limited
    • Smart Cells International Ltd
    • Viacord, LLC


In The News

  • As a partner stem cell bank, Smart Cells International Ltd collaborates with the charity Leukaemia & Myeloma Research UK (LMRUK). By participating in this agreement, qualified pregnant moms would have the option to freeze their baby's umbilical cord blood stem cells at the time of birth in case they are later required to treat the child or a sibling if they are a good match.

  • The Brazilian Patent Office has approved the patent application titled, "A method of generating cells which secrete Brain Derived Neurotrophic Factor (BDNF), Glial Derived Neurotrophic Factor (GDNF), Hepatocyte Growth Factor (HGF), and Vascular Endothelial Growth Factor (VEGF), wherein said cells do not secrete Nerve Growth Factor," according to Brainstorm Cell Limited a leading provider of adult stem cell therapeutics for neurode (NGF). The approved claims include a process for producing MSC-NTF cells (NurOwn).


Global Economic Impact

Request Insights
Despite Inflation & Fearing Recession, Businesses Across the Globe Expected to Do Better in 2023:

In 2023, market players might incur losses due to huge gap in currency translation followed by contracting revenues, shrinking profit margins & cost pressure on logistics and supply chain.
Controlling Inflation has become the first priority for global economies from last quarter of 2022 and to be followed in 2023. With skewed economic situations, rise in interest rate by governments to control spending and inflation, spiked oil and gas prices, high inflation, geo-political issues including U.S. & China trade war, Russia-Ukraine conflict to intensify the global economic issues.
The interest rates in the U.S. may be less sensitive in 2023 as compared to 2022; sigh of relief for businesses. Positive business sentiments, healthy business balance sheets, growth in construction spending (private construction value in 2022 stood at $1,429.2 billion, 11.7 percent (±1.0 percent) above the $1,279.5 billion spent in 2021, Residential construction in 2022 was $899.1 billion, up by 13.3 percent (±2.1 percent) from $793.7 billion in 2021, non-residential construction touched $530.1 billion, 9.1 percent (±1.0 percent) above the $485.8 billion in 2021.) showcases minimal impact of recession in the country.
Similarly, spiked spending in the European and major Asia economics including, India, China & Japan to showcase less impact on the global demand.

Author Credits:  Radhika Gupta, Shivam Bhutani

Key Questions Answered in the Report

1) What are the major factors driving the growth of the stem cell banking market?

Ans: The major factors driving the growth of the market are growing prevalence of cardiovascular disease, rise in number of people with Diabetes Type I, surge in approval of products by regulatory authorities, and others

2) What would be the CAGR of stem cell banking market over the forecast period?

Ans: The market size of stem cell banking is anticipated to attain a CAGR of ~11.20 % over the forecast period, i.e., 2023 – 2035.

3) What are the challenges affecting the stem cell banking market growth?

Ans: High operation cost, absence of proper handling such as freezing, storage, and warming, and inaccessibility of stem cell bank to people are estimated to be the growth hindering factors for the market expansion.

4) Which region will provide more business opportunities for growth of stem cell banking market in future?

Ans: The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

5) Who are the major players dominating the stem cell banking market?

Ans: The major players in the market are CBR Systems Inc., Global Cord Blood Corporation, Cordlife Group Limited, Cordvida, and more.

6) How are the company profiles selected?

Ans: The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.

7) What are the segments in the stem cell banking market?

Ans: The market is segmented by service type, utilization, cell type, bank type, and by region.

8) Which segment captures the largest market size in the bank type segment in the stem cell banking market?

Ans: The private segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

Let Us Hear About Your Requirements:

Submit Your Request For Proposal (RFP)

 Request Free Sample Copy